STAT December 18, 2025
Plus: A chat with Jared Holz, Mizuho’s health care market strategist
This is the 44th, and last, edition of the Biotech Scorecard newsletter in 2025.
By the way, in case you’re wondering, I will be making a pistachio cake with cream cheese frosting for Christmas dinner.
The old saw, the new saw
The old saw: Biotech will never attract a meaningful share of generalist investor capital because the sector is overstuffed with risky, development-stage companies that lose a ton of money.
The new saw: Development-stage biotechs are...
Today's Sponsors
Today's Sponsor